3,054
Views
5
CrossRef citations to date
0
Altmetric
Article

The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative

ORCID Icon, , , , , , , , , , , , , , , , , , , , , , ORCID Icon, , & ORCID Icon show all
Pages 1182-1188 | Received 15 Jun 2020, Accepted 31 Aug 2020, Published online: 12 Oct 2020

References

  • Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201.
  • Polanco PM, Ding Y, Knox JM, et al. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in patients with high-grade, high-volume disseminated mucinous appendiceal neoplasms. Ann Surg Oncol. 2016;23(2):382–390.
  • Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Cin Oncol. 2012;30(20):2449–2456.
  • Levine EA, Stewart JH, IV Russell GB, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg. 2007;204(5):943–953.
  • Sugarbaker PH. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Woodbury, NY: Cine-Med Publishing; 2012.
  • Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach . Ann Surg. 1994;219(2):112–119.
  • Sideris L, Mitchell A, Drolet P, et al. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg. 2004;52(2):19–43.
  • Elias D, Matsuhisa T, Sideris L, et al. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004;15(10):1558–1565.
  • Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia. 2007;23(5):431–442.
  • Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92(1):71–76.
  • SØrensen O, Flatmark K, Reed W, et al. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in pseudomyxoma peritonei. Eur J Surg Oncol. 2012;38(10):969–976.
  • Chua TC, Liauw W, Zhao J, et al. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis. Int J Clin Oncol. 2013;18(3):439–446.
  • Lam J, McConnell Y, Rivard J, et al. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg. 2015;210(3):424–430.
  • Beal EW, Ahmed A, Grotz T, et al. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020;219(3):478–783.
  • Zaidi MY, Lee RM, Gamboa AC, et al. Preoperative risk score for predicting incomplete cytoreduction: a 12-institution study from the US HIPEC collaborative. Ann Surg Oncol. 2020;27(1):156–164.
  • Baratti D, Kusamura S, Cabras AD, et al. Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer. 2013;49(15):3140–3148.
  • Marcotte E, Sideris L, Drolet P, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis. Ann Surg Oncol. 2008;15(10):2701–2708.
  • Soucisse ML, Liauw W, Hicks G, et al. Early postoperative intraperitoneal chemotherapy for lower gastrointestinal neoplasms with peritoneal metastasis: a systematic review and critical analysis. Pleura Peritoneum. 2019;4(3):20190007.
  • Huang Y, Alzahrani NA, Liauw W, et al. Early postoperative intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasms with pseudomyxoma peritonei: is it beneficial? Ann Surg Oncol. 2017;24(1):176–183.
  • McConnell YJ, Mack LA, Francis WP, et al. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol. 2013;107(6):591–596.
  • Tan GH, Ong WS, Chia CS, et al. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? Int J Hyperthermia. 2016;32(3):281–288.